Active Ingredient History

  • Now
Laniquidar (INN) is a third generation P-glycoprotein inhibitor that underwent clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It has been discontinued because of its low bioavailability and a high variability with how the patients responded to the drug.   Wikipedia

  • SMILES: COC(=O)c1cnc2C(=C3CCN(CCc4ccc(OCc5ccc6ccccc6n5)cc4)CC3)c7ccccc7CCn12
  • Mol. Mass: 584.72
  • ALogP: 6.49
  • ChEMBL Molecule:
More Chemistry
11c-laniquidar | laniquidar | r101933 | r 101933 | r-101933


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue